First primary care trial supports FeNO-guided asthma treatment

SOLNA, Sweden – 11 October, 2013 - Aerocrine AB (OMX Nordic Exchange: AERO) – A
new randomised clinical trial shows lower incidence of asthma exacerbations and
increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti
-inflammatory treatment.  The study has been published on the website of Journal
of Allergy and Clinical Immunology: In Practice (http://www.jaci
-inpractice.org/article/S2213-2198(13)00352-8/abstract).
A total of 187 non-smoking asthma patients (18-64 years) with perennial allergy
and on regular inhaled corticosteroid (ICS) treatment were recruited at 17
primary health care centres in Sweden, randomly assigned to two groups and
followed for one year. One group was treated with standard of care whereas
treatment of the patients in the other group were guided by FeNO. Aerocrine’s
patented FeNO test, with the NIOX® MINO® device was used in the study. In the
standard of care group FeNO was blinded for both patient and physician.

“FeNO-guided anti-inflammatory treatment enabled the physicians to optimize the
treatment with for example inhaled corticosteroids so that both over- and
undertreatment can be avoided. This may be a useful tool in long-term management
of patients with asthma”, says Dr Jörgen Syk, General Practitioner at Runby
primary care clinic, Stockholm, Sweden and being the principal investigator in
the study.

Overall, FeNO-guided management resulted in improved asthma symptom control and
reduced exacerbation frequency in adults with asthma. The FeNO-guided group
reported almost 50% fewer asthma exacerbations without an increase in the used
average dose of corticosteroids.

Although there was no difference in perceived quality of life (which was the
primary endpoint of the study) between the groups, the FeNO-guided group
reported fewer symptoms than the group following standard of care treatment.

“This is the third major, well controlled, blinded trial* to confirm that FeNO
is a useful biomarker for the management of asthma by reducing exacerbations and
managing the utilization of the appropriate medication at the correct time. This
information further substantiates and strengthens the clinical evidence behind
the American Thoracic Society (ATS) guidelines. These guidelines are also
endorsed by American College of Allergy, Asthma and Immunology (ACAAI) and the
American Academy of Allergy, Asthma and Immunology (AAAAI), said Scott Myers,
CEO Aerocrine AB.

Asthma is a chronic inflammatory airways disease that is characterized by
symptoms including wheezing and difficulty in breathing. Asthma is one of the
world’s most common and costly diseases; it affects 8-10 per cent of the
population and is associated with enormous healthcare expenditures that include
direct and indirect costs. The disease has no cure, and proper diagnosis and
management is crucial for improved quality of life for the patients. FeNO
measurement enables physicians to better assess and manage patients with
allergic airway inflammation.

For more information, contact:
Scott Myers, Chief Executive Officer, Aerocrine, Phone: +46 768 788 379
Dr Kathy Rickard, Chief Medical Officer Aerocrine, Phone : +1 919 749 6708

About Aerocrine
Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which
enables fast and reliable point-of-care measurement of airway inflammation. This
product plays a critical role in more effective diagnosis, treatment and follow
-up of patients affected with inflammatory airway diseases. Aerocrine is based
in Sweden with subsidiaries in the US, Germany, Switzerland and the UK.
Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007
(AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 10 am on October 11 2013.